Reduced m 6 A mRNA methylation is correlated with the progression of human cervical cancer

Xiuli Wang; Zenghui Li; Beihua Kong; Chen Song; Jianglin Cong; Jianqing Hou; Shaoguang Wang

doi:10.18632/oncotarget.22041

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of Concern

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

Reduced m⁶A mRNA methylation is correlated with the progression of human cervical cancer

Xiuli Wang, Zenghui Li, Beihua Kong _, Chen Song, Jianglin Cong, Jianqing Hou and Shaoguang Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:98918-98930. https://doi.org/10.18632/oncotarget.22041

Metrics: PDF 2564 views | HTML 5642 views | ?

Abstract

Xiuli Wang1,2,*, Zenghui Li2,*, Beihua Kong1, Chen Song3, Jianglin Cong2, Jianqing Hou2 and Shaoguang Wang2

1Department of Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China

2The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, P.R. China

3Department of Gynecology, Zhucheng Maternal and Child Health Hospital, Zhucheng, Shandong 262200, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Beihua Kong, email: [email protected]

Keywords: m⁶A RNA methylation; cervical cancer; cancer

Received: May 04, 2017 Accepted: October 02, 2017 Published: October 24, 2017

ABSTRACT

The m⁶A mRNA methylation involves in mRNA splicing, degradation and translation. Recent studies have revealed that reduced m⁶A mRNA methylation might promote cancer development. However, the role of m⁶A mRNA methylation in cervical cancer development remains unknown. Therefore, we investigated the role of m⁶A methylation in cervical cancer in the current study. We first evaluated the m⁶A mRNA methylation level in 286 pairs of cervical cancer samples and their adjacent normal tissues by dot blot assay. Then the role of m⁶A on patient survival rates and cervical cancer progression were assessed. The m⁶A level was significantly reduced in the cervical cancer when comparing with the adjacent normal tissue. The m⁶A level reduction was significantly correlated with the FIGO stage, tumor size, differentiation, lymph invasion and cancer recurrence. It was also shown to be an independent prognostic indicator of disease-free survival and overall survival for patients with cervical cancer. Reducing m⁶A level via manipulating the m⁶A regulators expression promoted cervical cancer cell proliferation. And increasing m⁶A level significantly suppressed tumor development both in vitro and in vivo. Our results showed that the reduced m⁶A level is tightly associated with cervical cancer development and m⁶A mRNA methylation might be a potential therapeutic target in cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22041

Publication Alerts

Research Papers:

Reduced m6A mRNA methylation is correlated with the progression of human cervical cancer

Abstract

Reduced m⁶A mRNA methylation is correlated with the progression of human cervical cancer